by Riley Nolan | Nov 4, 2021 | Featured, News
PROVIDENCE, RI, November 4, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. (“Maruho”) for EpiVax’s patented Tregitope technology. This marks an exciting step for Maruho and...
by Riley Nolan | Apr 21, 2021 | Featured, Thinking Out Loud -Blog
Tregitopes: What Did Nature Intend? Hey everybody, it’s a good idea to pay attention to the forces of Nature, right? When we discovered that IgG (as in monoclonals) contained Treg epitopes (and named them “Tregitopes”) in 2008, we knew that this discovery was a...
by Sarah Moniz | Jun 13, 2018 | Featured, News
NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...
by Annie De Groot | Apr 25, 2017 | Featured, News, Thinking Out Loud -Blog
EpiVax Signs First Commercial License for Tregitope Technology PROVIDENCE, R.I., April 25, 2017 – Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an undisclosed global...
by Annie De Groot | Apr 7, 2017 | News
Providence, RI April 7th, 2017 Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an unnamed global pharmaceutical company, for use in autoimmune disease and allergy. Tregitopes, pronounced...